glp 1 agonists oral FDA just approved orforglipron (Foundayo), Eli Lilly's GLP-1 receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest GLP-1 agonists approved for clinical

The subject of the use of BPC-157 for healing is explored here

Cytoplasmic staining was quantified after applying a collar of 69 m around the DAPI mask

GLP-1 drugs have unexpectedly been found to potentially help with addiction disorders such as those associated with nicotine and other substances (Manalac, Dec 2024)

10.1016/j.cortex.2019.12.026 199 RassuG.SorrentiM.CatenacciL.PavanB.FerraroL.GaviniE.et al (2023)

Moreover, a mild increased vascularity and patchy chronic inflammatory cell infiltrate in the connective tissue was observed in all our cases of MM and, interestingly, few pigmented dendritic melanocytes in the basal layer of the epithelium (cases 5 and 8) were observed

These metabolites are critical regulators of redox homeostasis, energy balance, and amino acid metabolismkey processes that are frequently disrupted in chronic metabolic diseases